Combination of calcipotriol and clobetasol propionate as a premixed ointment for the treatment of psoriasis.
The treatment of psoriasis requires good compliance, efficacy and low toxicity because of its long-term course and wide distribution. The aim of the study was to compare the efficacy of a once daily application of calcipotriol alone or calcipotriol and a superpotent steroid in a premixed form in patients with psoriasis. The monotherapy group of 32 patients with stable plaque psoriasis received 0.005% calcipotriol alone once daily. The combination group of 29 patients was treated once per day with 0.004% calcipotriol/0.01% clobetasol propionate as a premixed ointment. Eruption score of truncal involvement was evaluated. The combination regimen was more efficacious than the monotherapy as evidenced by (1) more patients with at least 50% reduction in the eruption score after 2 weeks, (2) lower eruption score after 6 weeks and later, and (3) less adverse effects. The combined once-per-day application of 0.004% calcipotriol/0.01% clobetasol propionate as a premixed ointment is a promising regimen for psoriasis.
Katoh
Norito
N
Department of Dermatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawara-machi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan. nkatoh@koto.kpu-m.ac.jp
Kishimoto
Saburo
S
D000279:Administration, Cutaneous; D002117:Calcitriol / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D002990:Clobetasol / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D003879:Dermatologic Agents / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009824:Ointments; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D012720:Severity of Illness Index; D016896:Treatment Outcome
D003879:Dermatologic Agents; D009824:Ointments; C055085:calcipotriene; D002990:Clobetasol; D002117:Calcitriol